PL3475303T3 - Formulacje przeciwciała anty-cd19 - Google Patents

Formulacje przeciwciała anty-cd19

Info

Publication number
PL3475303T3
PL3475303T3 PL17735440T PL17735440T PL3475303T3 PL 3475303 T3 PL3475303 T3 PL 3475303T3 PL 17735440 T PL17735440 T PL 17735440T PL 17735440 T PL17735440 T PL 17735440T PL 3475303 T3 PL3475303 T3 PL 3475303T3
Authority
PL
Poland
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
PL17735440T
Other languages
English (en)
Inventor
Patrick Garidel
Andreas Langer
Martin Hessling
Daniel WEINFURTNER
Bodo Brocks
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PL3475303T3 publication Critical patent/PL3475303T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL17735440T 2016-06-27 2017-06-27 Formulacje przeciwciała anty-cd19 PL3475303T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16176322 2016-06-27
EP17735440.4A EP3475303B1 (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations
PCT/EP2017/065819 WO2018002031A1 (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations

Publications (1)

Publication Number Publication Date
PL3475303T3 true PL3475303T3 (pl) 2021-12-06

Family

ID=56368805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17735440T PL3475303T3 (pl) 2016-06-27 2017-06-27 Formulacje przeciwciała anty-cd19

Country Status (26)

Country Link
US (2) US11352423B2 (pl)
EP (2) EP3475303B1 (pl)
JP (3) JP2019524671A (pl)
KR (2) KR102533875B1 (pl)
CN (2) CN109415440B (pl)
AU (2) AU2017289085B2 (pl)
CA (1) CA3029137A1 (pl)
CY (1) CY1124521T1 (pl)
DK (1) DK3475303T3 (pl)
ES (1) ES2874640T3 (pl)
HR (1) HRP20210945T1 (pl)
HU (1) HUE054296T2 (pl)
IL (1) IL263764B2 (pl)
LT (1) LT3475303T (pl)
MA (1) MA45450B1 (pl)
MD (1) MD3475303T2 (pl)
MX (1) MX2018016362A (pl)
PL (1) PL3475303T3 (pl)
PT (1) PT3475303T (pl)
RS (1) RS62035B1 (pl)
RU (1) RU2748024C2 (pl)
SG (2) SG11201810429UA (pl)
SI (1) SI3475303T1 (pl)
SM (1) SMT202100317T1 (pl)
WO (1) WO2018002031A1 (pl)
ZA (1) ZA201900483B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392561B (es) 2015-08-21 2025-03-24 Morphosys Ag Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
KR20230028571A (ko) 2016-10-28 2023-02-28 모르포시스 아게 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
US12544437B2 (en) 2019-10-04 2026-02-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant AAV
PH12022551009A1 (en) 2019-10-31 2023-03-20 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性cd16aバインダー
IL316747A (en) * 2022-05-03 2025-01-01 Xencor Inc Lymphoma treatment methods
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
IL322510A (en) * 2023-03-02 2025-10-01 Novetide Ltd Method for preparing GLP-1 peptides with controlled particle size
CN120754244B (zh) * 2025-09-10 2025-12-12 江苏豪森药业集团有限公司 一种含抗cd19抗体的药物组合物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
JP5401314B2 (ja) 2006-09-08 2014-01-29 メディミューン,エルエルシー ヒト化抗cd19抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JP2012518404A (ja) 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Cd19に結合するヒト化抗体及びその使用
RU2011140486A (ru) * 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
AU2014243700B2 (en) 2013-03-13 2019-01-24 Genentech, Inc. Formulations with reduced oxidation
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
HRP20241036T1 (hr) * 2013-11-21 2024-11-08 Genmab A/S Liofilizirana formulacija konjugata protutijelo-lijek
US20170028062A1 (en) * 2014-04-07 2017-02-02 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Also Published As

Publication number Publication date
MA45450B1 (fr) 2021-04-30
DK3475303T3 (da) 2021-05-31
IL263764B2 (en) 2024-09-01
IL263764B1 (en) 2024-05-01
KR20230074823A (ko) 2023-05-31
HUE054296T2 (hu) 2021-08-30
SG11201810429UA (en) 2018-12-28
AU2017289085B2 (en) 2024-07-18
WO2018002031A1 (en) 2018-01-04
RU2748024C2 (ru) 2021-05-19
EP3475303B1 (en) 2021-04-14
SMT202100317T1 (it) 2021-07-12
US11352423B2 (en) 2022-06-07
MD3475303T2 (ro) 2021-09-30
AU2017289085A1 (en) 2018-12-13
CY1124521T1 (el) 2022-07-22
RU2019100221A (ru) 2020-07-28
MX2018016362A (es) 2019-04-22
RU2019100221A3 (pl) 2020-11-30
CN109415440B (zh) 2022-12-06
CN115998859A (zh) 2023-04-25
RS62035B1 (sr) 2021-07-30
AU2024205042A1 (en) 2024-08-15
HRP20210945T1 (hr) 2021-09-17
JP7603201B2 (ja) 2024-12-20
JP2022119854A (ja) 2022-08-17
ZA201900483B (en) 2021-06-30
SG10201912369QA (en) 2020-02-27
KR20190021373A (ko) 2019-03-05
SI3475303T1 (sl) 2021-12-31
JP7824990B2 (ja) 2026-03-05
CN109415440A (zh) 2019-03-01
EP3475303A1 (en) 2019-05-01
LT3475303T (lt) 2021-06-25
CA3029137A1 (en) 2018-01-04
IL263764A (en) 2019-01-31
JP2024109816A (ja) 2024-08-14
JP2019524671A (ja) 2019-09-05
US20190322742A1 (en) 2019-10-24
PT3475303T (pt) 2021-06-25
US20220213190A1 (en) 2022-07-07
EP3909985A1 (en) 2021-11-17
ES2874640T3 (es) 2021-11-05
NZ748681A (en) 2025-06-27
KR102533875B1 (ko) 2023-05-18

Similar Documents

Publication Publication Date Title
IL272227A (en) Anti-tigit antibodies
IL269405A (en) Anti-sirp alpha antibodies
IL263764A (en) Anti-cd19 antibody formulations
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
PL3606954T3 (pl) Przeciwciała anty-LAG3
DK3504241T3 (da) Anti-cd3-antistofformuleringer
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
PT3443009T (pt) Anticorpos anti-tim-3 e composições
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3529269T3 (da) Antistof-konstruktioner
IL256099A (en) Antibody
DK3350218T5 (da) Polyomavirus-neutraliserende antistoffer
EP3319983C0 (en) TAU LINKING ANTIBODIES
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3484446T3 (da) Antistofsammensætninger
IL291164A (en) Anti-nme antibody
DK3481420T3 (da) Antistofformuleringer
IL257368A (en) Antibody
EP3579879A4 (en) ANTI-BODY ANTI-KIR3DL1
DK3484921T3 (da) Anti-IL-22R antistoffer